Search Results 81-90 of 17310 for GLP-1 therapy

  1. Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes - Mayo Clinic

    Discontinuation of a GLP-1RA or a GLP-1/GIP dual-agonist within 6 months of the screening visit following at least one month of treatment. Known autoimmune ...

  2. Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women with Obesity - Mayo Clinic

    Contraindications to GLP-1 receptor agonist therapy as per Tirzepatide (Zepbound ®) label. ... one and received treatment (active or placebo) in the last 30 days.

  3. Type 1 diabetes in children - Diagnosis and treatment - Mayo Clinic

    Treatment for type 1 diabetes includes: Taking insulin; Monitoring blood sugar; Eating healthy foods; Exercising regularly. You'll work closely with your ...

  4. Diabetic nephropathy (kidney disease) - Diagnosis and treatment - Mayo Clinic

    They include older diabetes medicines such as insulin. Newer drugs include Metformin (Fortamet, Glumetza, others), glucagon-like peptide 1 (GLP-1) receptor ...

  5. A Study To Test The Effect Of BI 456906 On Cardiovascular Safety In People With Overweight Or Obesity (SYNCHRONIZE™ - CVOT) - Mayo Clinic

    ... treatment works better than the current standard therapy. ... 1 trial. ... Previous treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists within 3 ...

  6. Glucagon (nasal route) - Side effects & dosage - Mayo Clinic

    However, safety and efficacy of glucagon nasal powder have not been established in children younger than 1 year of age. Geriatric. Appropriate studies performed ...

  7. Brain stereotactic radiosurgery - Mayo Clinic

    Some arise soon after treatment; others may be delayed. Early side effects may include: Fatigue. Fatigue is common after radiation and may peak within 1 to 2 ...

  8. Muscular dystrophy - Diagnosis & treatment - Mayo Clinic

    Learning that you or a loved one has muscular dystrophy can be very challenging. To help cope, find someone to talk with. You might feel comfortable sharing ...

  9. Study Evaluating The Safety And Efficacy Of Semaglutide, And The Fixed-Dose Combination Of Cilofexor And Firsocostat, Alone And In Combination, In Participants With Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (NASH) - Mayo Clinic

    - History of type 1 diabetes. - Treatment with a glucagon-like peptide-1 receptor agonist (GLP-1 RA) in the period from 90 days prior to the screening visit ...

  10. Irritable Bowel Syndrome Clinical Trials - Mayo Clinic Research

    The investigators' hypothesis is that therapy ... The objective of sub-study 1 was to characterize ... treatment, and novel targeted therapeutic strategies for FGID ...